.After raising $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on everyone market.The Eli Lilly-partnered biotech plan to specify on the Nasdaq under the sign “BIOA,” according to documents submitted along with the Stocks as well as Exchange Payment. The business has not publicly discussed an assumed financial amount for the offering.The clinical-stage firm promotes lead candidate azelaprag, a by mouth delivered little molecule slated to get into phase 2 testing in combination with semaglutide– sold by Novo Nordisk under trademark name Wegovy for fat burning– in the 1st one-half of following year. Semaglutide is actually likewise offered as Ozempic and Rybelsus through Novo for diabetic issues.
Apelin receptor agonist azelaprag is created to integrate effectively along with GLP-1 medicines, increasing weight loss while maintaining muscle mass. The investigational drug was located to become well-tolerated amongst 265 people all over eight stage 1 tests, depending on to BioAge.Previously, BioAge achieved the support of Lilly to operate a test blending azelaprag with the Significant Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is industried for diabetes mellitus as Mounjaro and Zepbound for effective weight loss. The companions are actually presently conducting a phase 2 test of azelaprag and tirzepatide, along with topline results assumed in the third quarter of 2025.The biotech is actually additionally organizing a the hormone insulin level of sensitivity proof-of-concept test analyzing azelaprag as a monotherapy in the first fifty percent of upcoming year to assist possible sign growth.
In addition, the provider plans to talk to the FDA for permission in the second one-half of 2025 to release individual testing for an NLRP3 prevention targeting metabolic illness and also neuroinflammation.BioAge’s anticipated move to everyone market adheres to a minor uptick in intended biotech IPOs from Bicara Therapeutics and also Zenas Biopharma. Zooming out, the recent IPO garden is actually a “combined image,” along with high quality firms still debuting on the general public markets, merely in decreased numbers, depending on to PitchBook.